2015
This discovery paper identified MOTS-c as a new hormone coded in mitochondrial DNA (the small set of genes inside your cells' energy engines). The researchers showed that MOTS-c targets skeletal muscle (the muscles you move), activates AMPK (a cell energy sensor), and prevents both age-related and diet-induced insulin resistance (when cells stop responding to insulin) and obesity in mice. This establishes it as a real metabolic regulator.
Lee C, Zeng J, Drew BG, Sallam T, Martin-Montalvo A, Wan J, Kim SJ, Mehta H, Hevener AL, de Cabo R, Cohen P
2016
This review confirmed MOTS-c's role as a 'mitochondrial hormone' (a hormone made by your cells' energy engines) with wide-ranging effects. It explained how MOTS-c blocks the folate cycle and purine biosynthesis (two steps in how cells make building blocks), leading to AMPK activation. That makes it a possible treatment target for obesity, diabetes, and age-related metabolic decline.
Lee C, Kim KH, Cohen P
2024
This study in marathon runners and mice found that MOTS-c levels track closely with aerobic exercise capacity. Endurance training raises MOTS-c release, which improves how well mitochondria (your cells' energy engines) work through AMPK/PGC-1α activation (PGC-1α is a protein that triggers the growth of new mitochondria). This suggests MOTS-c carries some of exercise's metabolic benefits.
Feng Y, Rao Z, Tian X, Hu Y, Yue L, Meng Y, Zhong Q, Chen W, Xu W, Li H, Hu Y, Shi R
2024
Researchers found that MOTS-c directly binds and switches on the enzyme CK2, which it needs for its muscle-protecting effects. The study also found that a natural MOTS-c variant (K14Q) that binds CK2 less well is linked to a higher risk of sarcopenia (age-related muscle loss) and type 2 diabetes. This is the first genetic link between MOTS-c and human metabolic disease.
Kumagai H, Kim SJ, Miller B, et al.
2026
This study showed that MOTS-c improves how well mitochondria (your cells' energy engines) perform in skeletal muscle through the PGC-1α and AMPK pathways. Importantly, it reduced mitochondrial reactive oxygen species (harmful byproducts of making energy) and oxidative damage (cell damage caused by those byproducts). This shows MOTS-c protects cells from the harmful byproducts of energy production.
Gudiksen A, Hansen CC, van der Stede T, et al.
2018
In cultured cells, MOTS-c moved from the mitochondria into the nucleus (the cell's control center) within about 30 minutes of metabolic stress such as glucose restriction, serum removal, or oxidative stress, and this movement depended on AMPK. Once in the nucleus, MOTS-c bound antioxidant response element (ARE) sequences (DNA stretches that switch on protective genes) in genes including HO-1 and NQO1 and interacted with NRF2 (a protein that switches on cell-defense genes), increasing the activity of those genes.
Kim KH, Son JM, Benayoun BA, Lee C
2020
In healthy men, MOTS-c in the blood was 11% lower in middle-aged men (45-55 y) and 21% lower in older men (70-81 y) than in young men (18-30 y). The age effect stayed statistically significant after adjusting for body composition and metabolic measures. MOTS-c in skeletal muscle moved the opposite way, being roughly 1.5-fold higher (about 1.5 times higher) in the older groups, and blood MOTS-c was not correlated with HOMA-IR (a measure of insulin resistance).
D'Souza RF, Woodhead JST, Hedges CP, Zeng N, Wan J, Kumagai H, Lee C, Cohen P, Cameron-Smith D, Mitchell CJ, Merry TL
2024
Alongside its main findings on pain behaviour, this mouse study checked organ safety after long-term MOTS-c injections into the belly cavity (intraperitoneal). Long-term dosing had little effect on measures of liver, kidney, blood-fat (lipid) and heart function, and no differences in tissue damage to liver, spleen, or kidney were seen between treated and control groups.
Yang L, Li M, Liu Y, Bai Y, Yin T, Chen Y, Jiang J, Liu S
2021
This review states that metformin lowers blood sugar in people with poorly controlled type 2 diabetes mainly by reducing the liver's sugar production, and reviews the patient studies that confirmed this. It also traces metformin's history from its 1957 introduction by Jean Sterne to FDA approval in 1994.
LaMoia TE, Shulman GI